Despite the promising anticancer activity offered by PD-1 and PD-L1 inhibitors, predicting tumor responses to PD-1/PD-L1 blockade remains a challenge given that not all patients derive benefit from this class of immunotherapy. The gene discussed is PDCD1; the disease is neoplasm.